Lyell Immunopharma, Inc.
LYELNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for LYEL. That does not mean none is planned.
Get an email about LYEL's next catalysts
Track Lyell Immunopharma (LYEL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 1 past
LYEL Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-2.06 | FQ end Sep/2026 | Call: tbd
Updated PiNACLE 3L+ R/R LBCL data in 44 efficacy-evaluable patients: ORR 91%, CR rate 77%; median DoCR and median PFS not reached; continued CR 92% at 6 months and 75% at 12 months; no Grade ≥3 CRS; Grade ≥3 ICANS 9%. Data accepted for ASH 2026.
Market Overview
Stock performance and key metrics
rondecabtagene autoleucel
Large B-cell Lymphoma
LYL314
Relapsed Non-Hodgkin Lymphoma
LYL273
Colorectal Cancer
Rondecabtagene autoleucel (ronde-cel)
Relapsed Non-Hodgkin Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rondecabtagene autoleucel | Phase 3 | Large B-cell Lymphoma | - | - |
LYL314 | Phase 2 | Relapsed Non-Hodgkin Lymphoma | - | - |
LYL273 | Phase 2 | Colorectal Cancer | - | - |
Rondecabtagene autoleucel (ronde-cel) | Phase 2 | Relapsed Non-Hodgkin Lymphoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Lyell Immunopharma, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Lyell Immunopharma, Inc.'s (LYEL) pipeline across Phase 3, Phase 2. Its lead program is rondecabtagene autoleucel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lyell Immunopharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Lyell Immunopharma, Inc. (LYEL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LYEL biotech catalysts?→
Add LYEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lyell Immunopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.